Monoclonal Antibodies against Tumor Metastases

Against Peritoneal Dissemination, Lymph node/Liver metastases

Advantages

  • Identified from 300 stage III gastric cancer patient’s resected specimens.
  • Potentially effective for other tumors; lung, colorectal, breast, pancreatic cancer, etc.
  • Companion diagnostic can be used.

Background and Technology

Gastric cancer (GC) is the second leading cause of cancer-related deaths worldwide.  Although limited treatment options including antibodies targeting receptors of the growth factors and the immuno-checkpoint inhibitors are currently available for advanced gastric cancer, their response rates remain unsatisfactory.  Thus novel anti-cancer agents with completely different mechanisms are indispensable for improvement of the treatment outcomes of GC patients.

Transmembrane Receptor-B has been identified via comprehensive transcriptome analysis of 300 resected tissues from stage III GC patients.  Receptor-B was significantly expressed in specimens of patients with poor prognosis compared with five year survivors without recurrence.

Data

  • Intraperitoneal administration of monoclonal antibodies against Receptor-B significantly reduced tumor growth of human GC peritoneal  dissemination model mice (fig).
  • Patient’s cancer tissues were stained by Immunohistochemistry.
  • Retrospective analysis by quantitative PCR data showed high predictive values to identify patients at risk of recurrences and poor prognosis.
  • Tissue microarray data demonstrated cancer-specific overexpression of receptor-B in breast cancer, lung cancer, pancreatic cancer and colon cancer.

9-12-1018

Patent

Pending (Unpublished)

Researcher

Dr. Mitsuro kanda    Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Japan.

Expectations

We are looking for a company to license and develop this technology. Detailed data can be disclosed under CDA.

Product No:TP-00782

Categories of Inventions

Disease Categories

Product Type

Updated
Published

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.